• SuperCom is an electronic monitoring solutions developer and provider that offers the PureSecurity(TM) Suite, a comprehensive range of products that include a domestic violence monitoring solution, a GPS tracking platform called PureTrack(TM), a house arrest enforcement solution, and an inmate monitoring solution
• The company holds that its advanced domestic violence monitoring solution could play a vital role for enhancing public safety measures, particularly in light of a recent cases emphasizing the critical need for effective response in domestic violence situations
• An Illinois appellate court recently upheld a $3 million jury award to the estate of the late Vanessa Taylor, who was allegedly killed by her boyfriend, after finding sufficient evidence that two officers “cared more about going home” than protecting Taylor

On June 30, 2015, about 25 hours after the Chicago Police Department (“CPD”) had responded to a domestic violence call at a West Side, Chicago, apartment, Vanessa Taylor was allegedly killed by her boyfriend, James Thomas. The death led to a wrongful death and survival action lawsuit against the City of Chicago, following which a Cook County jury found the city liable for Taylor’s death and awarded her estate $3 million, “which is believed to be a record civil judgment under the Illinois Domestic Violence Act,” according to an article in the Chicago Tribune (https://ibn.fm/Tpkau).

The jury found that Taylor’s death was caused by CPD’s breach of its duty to protect her under the Domestic Violence Act. When officers responded to the initial call, placed on June 28, they found Taylor’s boyfriend, James Thomas, in a mental health crisis that prompted them to transport him to the hospital. Once at the hospital, Thomas was given an antipsychotic sedative, administered a mental health examination by a physician, and discharged several hours later, court documents show (https://ibn.fm/rsBV3).

By the time he was discharged, however, the police officers had already left the hospital and had gone home despite the fact that, when they responded to the call earlier, Taylor had a black eye, according to court records. Furthermore, Thomas had allegedly cut the gas line in Taylor’s building and tussled with the officers, actions the court listed as charges Thomas could have faced in connection with the incident. After being discharged, Thomas returned to the West Side apartment where he committed the alleged crime.

Justices of the Illinois First District Appellate Court recently released a strongly worded opinion upholding the $3 million jury award to the estate of the victim after finding sufficient evidence that two CPD officers “cared more about going home for the day than protecting a domestic violence victim who was killed by her alleged abuser a short time later,” the article reads.

“In light of the recent appellate court decision emphasizing the critical need for effective response in domestic violence situations, SuperCom’s advanced technology solution could play a vital role in enhancing public safety measures,” wrote SuperCom (NASDAQ: SPCB) on its LinkedIn page (https://ibn.fm/3vfY3). SuperCom is a global leader in the field of electronics monitoring (“EM”). The company offers the PureSecurity(TM) Suite, a comprehensive range of products that include a domestic violence monitoring solution, a GPS tracking platform called PureTrack(TM), a house arrest enforcement solution, and an inmate monitoring solution.

“These innovative tools are designed to provide law enforcement and criminal justice agencies with real-time data and analytics, helping prevent tragic outcomes by ensuring constant monitoring and swift response in critical situations. SuperCom’s technology demonstrates a commitment to public safety and the protection of vulnerable individuals, aligning closely with the heightened need for effective and proactive measures in domestic violence cases,” SuperCom explained in the post.

SuperCom’s life-saving domestic monitoring solution is designed to monitor the movement of domestic violence aggressors, acting as a protective front line for victims. It combines several SuperCom technologies, including the PureProtect(TM) smartphone app, the PureTag ankle bracelet, and the PureMonitor software (https://ibn.fm/d5HYc).

The PureProtect app is designed for victims. It detects proximity violations and alerts the victims whenever the domestic violence perpetrators near their location. The app uses advanced zoning, proximity, alerting, and management capabilities to both enforce a safe distance between the victims and perpetrators and update the former of the latter’s whereabouts. It achieves this without violating the victims’ privacy. The app also supports the latest GPS, cellular, Wi-Fi, and Bluetooth technologies, enabling it to communicate with the aggressor-worn PureTag ankle bracelet, which beams signals that report the wearer’s exact location.

Completing the list of technologies that make up SuperCom’s domestic monitoring solution is the PureMonitor software meant for law enforcement officers. The software tracks the location of the aggressors and victims, logging all real-time and historical instances when proximity breaches occur. It also alerts law enforcement officers of breaches and has reporting and analytics capabilities.

The PureProtect electronic domestic violence monitoring solution provides all the information needed to protect victims and enforce court restrictions. Its advanced zoning and alerting capabilities make it a vital tool in helping enforce safety measures and preventing avoidable tragic outcomes like domestic violence-related deaths.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• D-Wave’s completion of the SOC 2 Type 2 audit makes it the first full-stack quantum computing provider to achieve this compliance
• The company is deeply committed to data security as customers adopt the production use of its quantum computing solutions
• Going forward, D-Wave will perform annual SOC 2 Type 2 assessments, making the latest report available to current and potential clients upon completing a nondisclosure agreement

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the successful completion of its SOC 2(R) Type 2 audit on December 7, 2023. This compliance verification, which evaluates a number of operational factors including processing integrity and security controls, is of growing importance, especially as D-Wave increases commercial customer adoption and production use of its quantum computing solutions. This notable achievement makes D-Wave the first full-stack quantum computing provider to achieve SOC 2 Type 2 compliance. The Type 2 compliance follows D-Wave’s successful SOC 2 Type 1 audit in March 2023 (https://ibn.fm/XDoPR).

D-Wave CEO Dr. Alan Baratz said this was a pivotal moment for quantum computing, as the company’s customers are moving full-steam ahead into enterprise-scale adoption and deployment. “SOC 2 compliance is a key part of our production leadership, as it ensures commercial-grade security measures are established and regularly reviewed,” Baratz said. “With customers increasingly incorporating and using our quantum solutions to support daily operations, this level of data protection and security is paramount.”

The completion of the audit comes at a time when business leaders are being held more accountable for how third parties handle private information and need to ensure that the services they use to process data meet federally regulated mandates around security control and the effectiveness of the controls over time. Customers seek trusted vendors that help reduce risk and meet standards like SOC 2 as they consider where to run business-critical applications.

A-LIGN, a technology-enabled security and compliance partner trusted by more than 2,500 global organizations to help mitigate cybersecurity risks, conducted D-Wave’s SOC 2 Type 2 audit. Established by the American Institute of Certified Public Accountants (“AICPA”), the SOC 2 examination was designed for organizations of any size, regardless of industry and scope, to ensure the personal assets of potential and existing clients are safe. The SOC 2 reports are recognized internationally and verify that the company’s infrastructure, software, people, data, policies, procedures, and operations have been formally reviewed.

“Congratulations to D-Wave for completing its SOC 2 audit, a widely recognized signal of trust and security,” said Steve Simmons, COO of A-LIGN. “It’s great to work with organizations like D-Wave, who understand the value of expertise in driving an efficient audit and the importance of a high-quality final report.”

The company’s relentless pursuit of practical quantum computing has resulted in its technology being used by some of the world’s most advanced enterprises, including Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin.

D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, including more than 210 issued U.S. patents. The company has published more than 225 peer-reviewed papers in leading scientific journals.

D-Wave will perform annual SOC 2 Type 2 assessments in the future, making the latest report available to current and potential clients upon completing a nondisclosure agreement.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding D-Wave’s future SOC 2 Type 2 assessments, and the availability of the related reports to current and potential customers. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including  general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

Social media marketing professionals, executives, businesses, and enthusiasts, are invited to attend the GSMI Social Media Strategies Summit 2024 being held as a virtual event on February 28-29, 2024. This virtual event will be attended by acclaimed social media industry leaders who will share their in-depth insights for creating winning digital marketing campaigns.

SMSSummit is a coveted social media conference platform that benefits several industry verticals and businesses by targeting greater audience reach. The conference focuses on a targeted audience of decision-makers in the social media industry. Senior marketing professionals share their experience and knowledge of time-tested social media strategies. Leverage this social media summit platform for networking and connecting with senior marketers who set the trends of the industry.

The virtual event agenda includes:

• How to create short-form engaging videos that capture audience attention.
• Understand how influencer partnerships work for all types of brands.
• Learn ways to promote transparency in marketing campaigns and conduct ethical social media practices.
• Get acquainted with new strategies to keep social marketing campaigns fresh and reach unique audiences.
• Leverage the power of novel advertising ideas and get inspired to create engaging content.
• Unleash creativity and discover the best opportunities to promote brands on social media.
• Learn the best strategies and trends for marketers in 2024 and beyond.

The Summit starts with a welcome remark from the Summit Emcee. This will be followed by speaker sessions, panel discussions, networking rounds, meetings, and open discussions on the latest content planning and creation strategies. Attendees will learn how to scale the business’s efficiencies, improve marketing campaigns, and reach their business goals using holistic social media strategies.

To know more, please visit https://ibn.fm/1HbAx.

• Cyber attacks can cost corporations millions of dollars, endangering critical sensitive information, causing major operational headaches, and affecting hard-won corporate reputations
• Microsoft recently announced detection of a cyberattack that compromised the company’s corporate emails – an attack found to be launched by a Russian state-sponsored group referred to as Midnight Blizzard
• Sekur Private Data Ltd. offers consumers, businesses, corporations, and governments, Swiss-hosted solutions for secure communications and secure data management without the use of third-party cloud services

Cybersecurity attacks can cost corporations more than significant amounts of money – they can come with hidden costs like an increase in insurance premiums, operational disruption or destruction, lost value in customer relationships, and more (https://ibn.fm/oWoDG). It isn’t just small businesses that are vulnerable to attacks. In recent years, large corporations that devote significant effort in support of security are seeing just how vulnerable they can be to cyberattacks, many of which stem from hackers gaining entry through corporate emails.

Most recently, an email cyberattack was launched against Microsoft, by a group named Midnight Blizzard, a Russian state-sponsored actor also referred to as Nobelium. On January 12, Microsoft detected the attack which began in late November, compromising some of its corporate email accounts (https://ibn.fm/xwd1w). The hackers utilized a technique called a “password spray attack,” where a user uses a single common password against multiple accounts on the same application. According to reports, the hackers were targeting email accounts to obtain information about Midnight Blizzard.

For consumers, businesses, corporations, and governments looking to ward off attacks – there is a subscription option available. Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management, offers a suite of secure cloud-based storage, disaster recovery, document management, encrypted email, and secure communication tools that do not rely on third-party cloud services.

Sekur’s products include:

• SekurMail(R) with SekurSend/SekurReply: an encrypted email service offering a private, safe, and powerful tool to communicate with everyone within or outside the Sekur ecosystem. SekurMail protects personal information and communications from being accessed by unauthorized parties.
• SekurVPN(R): a secure, encrypted connection between client’s devices and the internet, giving safe access to the web by routing connections through the company’s wholly-owned Swiss servers. All data sent and received is hidden from prying eyes, including the client’s Internet Service Provider, potential hackers, government surveillance agencies, and more.
• SekurMessenger(R): a Swiss-hosted private and secure messaging communications app that provides secure and private chat, self-deleting chat, voice recording, and file transfer via any mobile device, tablet, or desktop computer. The app is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged.

Sekur offers customers peace of mind – with all customer information remaining confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based, or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

Sekur’s entire suite of encrypted email, secure messaging, and internet privacy solutions were designed to be user-friendly, while providing customers with unparalleled security solutions – stopping attacks before they happen. Sekur sells its products through its websites www.Sekur.com and www.SekurSuite.com, as well as through approved distributors and telecommunications companies worldwide.

For more information, visit the company’s website at www.SekurPrivateData.com, or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle
• The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS
• With plans to move forward on many fronts for the clinical development of CNM-Au8, 2024 looks bright for Clene

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”).

The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function.

ALS is among the most aggressive neurodegenerative diseases, in which the progressive loss of motor neurons can lead to death between 2-5 years of diagnosis. Although there are now three FDA approved drugs for the treatment of ALS, there is still great need for a drug that can slow disease progression and significantly impact survival.

Benjamin Greenberg, M.D., Clene’s Head of Medical, said that, as the company continues to analyze data from its RESCUE-ALS and Healey-ALS Regimen C phase 2 clinical programs, the evidence supports that CNM-Au8(R) treatment improved survival in people living with ALS. “We are also encouraged that the recently disclosed long-term NfL biomarker decreases are consistent with delayed clinical time-to-event outcomes,” Greenberg added.

As Clene advances, it also announced long-term results from its Phase 2 VISIONARY trial in MS, demonstrating long-term benefits on visual acuity and cognition. Lead clinician and MS clinician-scientist Michael Barnett of Sydney noted the results as “unprecedented.”

The CNM-Au8 development pathway for ALS has included:

• REPAIR-MS and REPAIR PD, two Phase 2 brain imaging studies that featured oral administration of CNM-Au8 for 12 weeks
• Improvements in brain energy metabolites in participants with MS and PD
• Evidence of target engagement, using an oral therapy to change brain energy potential

RESCUE-ALS, a nine-month, Phase 2 study:

• Randomized and placebo-controlled
• Investigated CNM-Au8 for efficacy and safety in early-stage ALS participants
• Primary endpoint: electrophysiological measure for motor unit preservation
• An unanticipated discovery during the trial: stable motor unit function in bulbar-onset ALS patients early in their disease with no detectable motor unit compromise in arms and legs, resulting in underpowering of the trial for primary endpoint
• First evidence of survival benefit and slowing of clinical worsening with CNM-Au8 treatment

HEALEY-ALS Platform trial, a six-month, Phase 2 study

• CNM-Au8 selected alongside three other ALS drugs, comprising the first four regimens of the Platform trial
• Six-month Phase 2 study; Randomized and placebo-controlled
• Investigated CNM-Au8 for efficacy and safety in participants with ALS
• Primary endpoint: change in ALSFRS-R (an instrument for evaluating the functional status of patients with Amyotrophic Lateral Sclerosis, and used to monitor functional change in a patient over time)
• No drug regimen in the Healey Trial has met primary endpoint, to date
• CNM-Au8 met the secondary endpoint of survival
• Ongoing long-term analyses of CNM-Au8 show impressive survival benefit and clinical improvement
• Significant reductions in levels of key biomarker Neurofilament light (“NfL”) with CNM-Au8 treatment during both the six-month period and one-year long-term open label period; CNM-Au8 is the first ALS drug investigated in a heterogenous ALS population to reach significance on this important ALS biomarker

The company is continuing to evaluate emerging long-term data from the RESCUE and HEALEY long term extension and their expanded access protocols (“EAP”) in ALS. Clene has announced plans for its global Phase 3 trial in ALS and is opening a new NIH-funded EAP for participants with ALS who do not qualify to participate in clinical trials in 2024.

In terms of safety, the company has accrued data on over 500 years of human subject exposure to CNM-Au8 from its clinical programs and compassionate use early access programs (FDA-approved EAPs) to date, with no serious safety signals being associated with drug treatment.

During 2024, Clene will work with the U.S. FDA to consider the strength of Clene’s data, while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• SOBRsafe’s alcohol detection technology can improve behavioral outcomes and help save lives
• Navix Health, a leading provider of innovative behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating SOBRsafe’s transdermal detection solutions into Navix Hub(TM)
• SOBRsafe’s products include SOBRsafe(TM), SOBRcheck(TM), and SOBRsure(TM)

SOBRsafe (NASDAQ: SOBR), a provider of advanced transdermal alcohol detection technology, recently announced that Navix Health, a leading provider of behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating the company’s transdermal detection solutions into Navix Hub(TM). With the integration of SOBRsafe into Navix Hub, customers can augment current operations with touch-based alcohol monitoring, with the results flowing directly into their client records platform. The collaboration marks a significant milestone in advancing digital health and enhancing patient-centric care (https://ibn.fm/38npo).

Dave Gandini, Chairman and CEO of SOBRsafe, said the company’s goal is to empower positive outcomes. “In this, we are wholly aligned with Navix Health, and we believe the integration with Navix Hub(TM) positions both our organizations to create maximum benefit through actionable alcohol intelligence. We are excited to partner with Navix Health, and we look forward to providing value to their customers industry-wide,” Gandini added.

SOBRsafe’s alcohol detection technology can improve workplace safety and provide advanced screening and monitoring solutions for the behavioral health industry. The company has developed a patent-pending alcohol detection device called SOBRcheck(TM) to detect alcohol in humans with just a single touch of the finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol through the user’s skin. No breath, blood, or urine samples are required – making it a hygienic alternative to traditional breathalyzers.

SOBRsafe’s technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data. The company’s products include:

• SOBRsafe(TM) – The company’s patent-pending platform for non-invasive alcohol detection, with real-time reporting and historical data aggregation. SOBRsafe is a solution that has broad potential applications across all industries, but with an immediate focus in behavioral health and justice.
• SOBRcheck(TM) – The company’s stationary identification and alcohol detection product provides quick, specific, point-of-care screening. The device verifies user identity and determines the presence or absence of alcohol, providing administrators with immediate, actionable results, delivered securely.
• SOBRsure(TM) – The company’s transdermal, alcohol-detecting wearable band that provides continuous monitoring, discreetly detecting and instantaneously reporting the presence or absence of alcohol by the band wearer. SOBRsure also provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

SOBRcheck and SOBRsure revenue models consist of flexible structures ensuring monthly recurring revenue. The SOBRsafe products have a powerful backend data platform, providing humane, passive and connected alcohol detection for the behavioral health and justice markets, and for licensing, integration and consumers.

The partnership between Navix Health and SOBRsafe combines expertise to offer comprehensive digital health solutions to address the evolving needs of patients, healthcare providers and stakeholders in the healthcare industry. By integrating SOBRsafe’s advanced alcohol monitoring technology with Navix Health’s robust EMR, both companies aim to enhance patient care, increase compliance and promote better health outcomes.

For more information, visit the company’s website at www.SOBRsafe.com. 

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• Lexaria, a global innovator in drug delivery platforms, has announced its GLP-1 research plans for the 2024 calendar year
• The company will kick off its chronic dosing animal study in March/April, followed by the human pilot study #2, kicking off at around the same time
• The third human pilot study will start in May/June followed by a chronic dosing human study that will involve 70-90 pre-diabetic and type-2 diabetic human patients
• These studies will evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced its research plans for the evaluation of its patented DehydraTECH(TM) technology for the improved delivery of GLP-1 drugs designed to support prospective commercial partnering with global pharmaceutical companies.. This builds on the success achieved from a recent human pilot study, which yielded impressive results, demonstrating superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced GLP-1 drug, semaglutide, which is currently available commercially as Rybelsus(R) (https://ibn.fm/uOdpf).

Kicking off at the end of Q1 or the beginning of Q2 is Lexaria’s chronic dosing animal study – an obese rat diabetic-conditioned study that will run for 12 weeks. The study will involve approximately 12 study arms and 6-10 animals per arm. It will also explore varied DehydraTECH formulations of semaglutide and liraglutide, alone and together with DehydraTECH-CBD, to evaluate overall efficiency.

Lexaria will also kick off human pilot study #2 in March/April. This study will involve up to 8 healthy volunteers and seek to explore the effectiveness of a single dose of oral ingested DehydraTECH-semaglutide capsules. It will seek to determine whether GLP-1 drug absorption via this route is effective and well tolerated as an alternative to the conventional oral ingestible route. It will evaluate blood sugar control, tolerability, and PK, with the DehydraTECH compositions compound-formulated using commercially available Rybelsus tablets as the semaglutide input material.

The third human pilot study will be in May/June, studying a single dose of orally ingested DehydraTECH-tirzepatide capsules to evaluate tolerability, PK, and blood sugar. The capsules will be compound-formulated using Zepbound(R). This product is currently administered by injection only but will be used as an input material to produce the capsules used for the study. This will set Lexaria up for its chronic dosing human study, which will involve 70-90 pre-diabetic and type-2 diabetic human patients, dosing daily using oral DehydraTECH capsules for 12 weeks. The study will also evaluate tolerability, PK, weight loss, blood sugar levels, and more.

The chronic dosing human study’s primary goal will be to compare DehydraTECH-processed semaglutide capsules to DehydraTECH-CBD capsules alone and together in combination, relative to a placebo control over an extended period. Insights from this study will also inform the company’s long-term stability testing, which will seek to explore the chemical and microbiological purity and stability of select DehydraTECH compositions that it prepares for this and future animal and human studies.

These studies highlight what is set to be a significant year for Lexaria. The ambitious goals show confidence in its DehydraTECH technology and its viability in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The hoopla surrounding crypto offerings’ highs and lows has attracted scores of new investors in a sort of modern-day gold rush, but the unfamiliarity of the sector to many traditional investors has been off-putting
• Utah-based Diamond Lake Minerals Inc. is redefining itself to attract digital asset-wary investors, by imbuing real world asset subsidiaries with security token offerings registered with the U.S. Securities and Exchange Commission (“SEC”)
• The company’s board members are experienced professionals, and its CEO has been ranked among the world’s Top 10 CEOs for three consecutive years recently by Adria Management, LLC in its World CEO Rankings Awards
• The popularity of DLMI’s approach has built a fan base, significantly increasing the company’s share price within just a few months

Salt Lake City-based company Diamond Lake Minerals (OTC: DLMI) is becoming a rapidly evolving success in the digital asset sector as it redefines its purpose and sets a course to bring digital-wary investors into regulated security token offerings (“STOs”) through a multi-strategy umbrella vision.

CEO Brian J. Esposito was ranked among the world’s Top 10 CEOs between 2020 and 2022 by Adria Management, LLC, and the company’s leadership team is guided by successful industry veterans (https://ibn.fm/UoGdM).

“We’re going to create a powerful parent umbrella company that has tremendous assets on its balance sheet as we continue to build and grow. Wonderful subsidiaries that we identify as great targets for our shareholders,” Esposito told Benzinga. “If you look at our board and the amount of wonderful icons that are very seasoned and very respected in their industries, having them support our vision and support our subsidiaries should give us a lot of strength and access and opportunities to help these companies really grow.”

DLMI’s vision entails operating, acquiring, building and supporting a large variety of companies in an industry-agnostic approach that provides DLMI investors an opportune gateway into all its divisional products.

Since the subsidiaries are each imbued with SEC-registered STOs through the regulated security token exchange INX, the company’s approach serves as a bridge for digital asset-uncertain investors to cross over to digital tokens without having to navigate the complexities of setting up a digital wallet and becoming hyper-attuned to the movements of crypto offerings.

“So we’re combining traditional securities with the future of digital assets in a regulated environment,” Esposito said. “I think this is what’s going to allow people to understand that this is the movement that’s happening. It is real. … We can open up capital to investors around the world through INX that typically wouldn’t have access to our types of vehicles as a public company in the United States, and that trades 24/7.”

DLMI aims to create a powerful parent umbrella company by ensuring its vertically integrated subsidiaries are potentially valuable targets for shareholders in sectors spanning music and other aspects of the entertainment industry, media, healthcare, real estate and a variety of other trades.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• A coalition of military veterans’ organizations is joining a growing number of entities encouraging the U.S. DEA to reschedule cannabis
• The call to reschedule cannabis has gained momentum since the U.S. HHS sent a letter to the DEA supporting the change
• Operating as MedCana, Software Effective Solutions has five divisions focused on pharmaceutical cannabis production

A growing number of organizations are calling for the rescheduling of cannabis from a Schedule I substance per the Controlled Substances Act (“CSA”) to a Schedule III substance. The most recent group to voice is support of the change is a coalition of military veterans (https://ibn.fm/FgMtF). Companies operating in the cannabis space, including Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), are paying close attention to the mounting demand because the rescheduling would significantly change the landscape.

“A coalition of military veterans’ organizations is pushing President Joe Biden to ensure that the ongoing administrative review into marijuana’s scheduling status is completed in a ‘timely manner’ and also take steps to ‘counter’ misinformation while pursuing broader reform,” reported a recent Marijuana Moment article. “In a letter sent to the president last week, multiple veterans-focused groups expressed appreciation for his directive initiating the marijuana review last year, which led the U.S. Department of Health and Human Services (‘HHS’) to recommend that cannabis be moved from Schedule I to Schedule III of the Controlled Substances Act.”

The article quoted a letter from the group noting that “this process represents a significant opportunity for our nation to lead with science over fear, and begin righting the wrongs of prohibition. . . . The actions taken by your administration and HHS have been historic, and lay the groundwork for the significant work ahead, including the need to ensure that the Drug Enforcement Administration (‘DEA’) expeditiously accepts the scientific and medically founded recommendation.”

The call for cannabis rescheduling on the CSA list is not new, but it has gained momentum since the U.S. HHS sent a brief letter to the head of the U.S. Drug Enforcement Administration. “The letter, obtained via Freedom of Information Act (‘FOIA’) request by Law360 reporter Sam Reisman, confirmed certain previously reported details such as the date of the correspondence, August 29, [2023,] and the author, HHS Assistant Secretary for Health Rachel Levine,” reported Marijuana Moment (https://ibn.fm/jHIWw).

“But it was redacted to exclude the substance of the message such as the scheduling recommendation itself, as well as the scientific review portion that was attached to the letter,” the article continued. However, “HHS is believed to have advised DEA to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (‘CSA’), and the law enforcement agency is now carrying out its own review before making a final determination.”

A change in the rescheduling would almost certainly benefit Software Effective Solutions, a global infrastructure and holding company in the cannabis industry. Operating as MedCana, the company currently has five divisions focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. The company is committed to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

• Correlate Energy, a publicly traded distributed energy solutions company, is taking advantage of the expanding renewable energy landscape and is helping drive its adoption
• Correlate has positioned itself as the go-to renewable energy solution, leveraging its three-pronged strategy that allows companies to make the move to highly efficient energy use and renewables, while minimizing transition costs
• This comes as Amazon was recently ranked the largest corporate buyer of renewable energy in the world in 2023, spear-heading the movement toward renewable energy adoption and reliance

Correlate Energy (OTCQB: CIPI), a publicly traded company capitalizing on America’s accelerating move toward cost effective renewable energy use, is looking to take advantage of the changing landscape and the growing reliance on renewable energy. As a company that understands this industry inside and out, Correlate is not only riding this wave but also helping drive it by identifying high-impact areas for improvement, addressing them, and delivering results. This has seen the company’s products and services adopted by various legacy companies across the U.S., a testament to its overall value proposition.

Globally, the world is witnessing a shift and a growing adoption of renewable energy. This has been spear-headed by industry leaders, with Amazon ahead of them all. Given its declaration to reach net zero by 2040, the company has aggressively pushed to adopt renewable energy sources. This resolve saw it become the world’s largest corporate buyer of renewable energy for the 2023 calendar year. It also saw the company invest in over 100 new solar and wind energy projects, bringing the total number of wind and solar projects backing it to 500 globally and generating over 77,000 GWh of clean energy each year (https://ibn.fm/mepat).

“More than 90% of our operations were powered by renewables last year, but we’re not done,” noted Adam Selipsky, AWS CEO.

“We’re focused on continuing to find innovative ways to bring new projects online, address grid constraints, and work with policymakers to mitigate the impacts of climate change, all of which is helping Amazon move closer to achieving 100 percent renewable energy by 2025,” he added.

Correlate has positioned itself as the go-to renewable energy solution. Through its unique three-pronged engineering and financing strategy, companies can make the move to highly efficient energy use and renewables, while minimizing transition costs. Correlate seeks to finance, develop, and profitably sell localized clean energy solutions and microgrids to industrial, commercial, and residential customers. It also seeks to retain ownership of some of these energy systems, ultimately extending upfront cost savings to the customer while realizing ongoing, reliable cash flow.

It is projected that renewable energy growth will come primarily via decentralized systems in the next ten years, fitting in with what Correlate offers. With the company’s first-mover advantage, Correlate is carving out a significant market share and asserting itself as the go-to company with these specific products and services. This, in addition to its aggressive push in the market, reflects its commitment to becoming one of the industry’s key leaders. It also reflects its ambitious plans for 2024 and beyond and its commitment to achieving them.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI